34587977|t|Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer.
34587977|a|BACKGROUND: Castration-resistant prostate cancer (CRPC) is associated with a very poor prognosis, and the treatment of which remains a serious clinical challenge. METHODS: RNA-seq, qPCR, western blot and immunohistochemistry were employed to identify and confirm the high expression of indolethylamine N-methyltransferase (INMT) in CRPC and the clinical relevance. Chip assay was used to identify Histone-Lysine N-Methyltransferase (SMYD3) as a major epigenetic regulator of INMT. LC-MS/MS were used to identify new substrates of INMT methylation in CRPC tissues. Gene knockdown/overexpression, MTT and mouse cancer models were used to examine the role of INMT as well as the anticancer efficacy of INMT inhibitor N,N-dimethyltryptamine (DMT), the SMYD3 inhibitor BCl-12, the selenium compounds methaneseleninic acid (MSA) and Se-(Methyl)selenocysteine hydrochloride (MSC), and the newly identified endogenous INMT substrate Bis(7)-tacrine. RESULTS: We found that the expression of INMT was highly increased in CRPC and was correlated with poor prognosis of clinical prostate cancer (PCa). INMT promoted PCa castration resistance via detoxification of anticancer metabolites. Knockdown of INMT or treatment with INMT inhibitor N,N-dimethyltryptamine (DMT) significantly suppressed CRPC development. Histone-Lysine N-Methyltransferase SMYD3 was a major epigenetic regulator of INMT expression, treatment with SMYD3 inhibitor BCl-121 suppressed INMT expression and inhibits CRPC development. Importantly, INMT knockdown significantly increased the anticancer effect of the exogenous selenium compounds methaneseleninic acid (MSA) and Se-(Methyl)selenocysteine hydrochloride (MSC) as well as the endogenous metabolite Bis(7)-tacrine. CONCLUSIONS: Our study suggests that INMT drives PCa castration resistance through detoxification of anticancer metabolites, targeting INMT or its regulator SMYD3 or/and its methylation metabolites represents an effective therapeutic avenue for CRPC treatment.
34587977	10	14	INMT	Gene	21743
34587977	98	113	prostate cancer	Disease	MESH:D011471
34587977	127	163	Castration-resistant prostate cancer	Disease	MESH:D064129
34587977	165	169	CRPC	Disease	MESH:D064129
34587977	401	436	indolethylamine N-methyltransferase	Gene	21743
34587977	438	442	INMT	Gene	21743
34587977	447	451	CRPC	Disease	MESH:D064129
34587977	548	553	SMYD3	Gene	69726
34587977	590	594	INMT	Gene	21743
34587977	645	649	INMT	Gene	21743
34587977	665	669	CRPC	Disease	MESH:D064129
34587977	710	713	MTT	Chemical	MESH:C070243
34587977	718	723	mouse	Species	10090
34587977	724	730	cancer	Disease	MESH:D009369
34587977	771	775	INMT	Gene	21743
34587977	814	818	INMT	Gene	21743
34587977	829	851	N,N-dimethyltryptamine	Chemical	MESH:D004130
34587977	853	856	DMT	Chemical	MESH:D004130
34587977	863	868	SMYD3	Gene	69726
34587977	879	885	BCl-12	Chemical	-
34587977	891	899	selenium	Chemical	MESH:D012643
34587977	910	931	methaneseleninic acid	Chemical	MESH:C008493
34587977	933	936	MSA	Chemical	MESH:C008493
34587977	942	981	Se-(Methyl)selenocysteine hydrochloride	Chemical	-
34587977	983	986	MSC	Chemical	-
34587977	1025	1029	INMT	Gene	21743
34587977	1040	1054	Bis(7)-tacrine	Chemical	MESH:C122128
34587977	1097	1101	INMT	Gene	21743
34587977	1126	1130	CRPC	Disease	MESH:D064129
34587977	1182	1197	prostate cancer	Disease	MESH:D011471
34587977	1199	1202	PCa	Disease	MESH:D011471
34587977	1205	1209	INMT	Gene	21743
34587977	1219	1222	PCa	Disease	MESH:D011471
34587977	1304	1308	INMT	Gene	21743
34587977	1327	1331	INMT	Gene	21743
34587977	1342	1364	N,N-dimethyltryptamine	Chemical	MESH:D004130
34587977	1366	1369	DMT	Chemical	MESH:D004130
34587977	1396	1400	CRPC	Disease	MESH:D064129
34587977	1449	1454	SMYD3	Gene	69726
34587977	1491	1495	INMT	Gene	21743
34587977	1523	1528	SMYD3	Gene	69726
34587977	1539	1546	BCl-121	Chemical	-
34587977	1558	1562	INMT	Gene	21743
34587977	1587	1591	CRPC	Disease	MESH:D064129
34587977	1618	1622	INMT	Gene	21743
34587977	1696	1704	selenium	Chemical	MESH:D012643
34587977	1715	1736	methaneseleninic acid	Chemical	MESH:C008493
34587977	1738	1741	MSA	Chemical	MESH:C008493
34587977	1747	1786	Se-(Methyl)selenocysteine hydrochloride	Chemical	-
34587977	1788	1791	MSC	Chemical	-
34587977	1830	1844	Bis(7)-tacrine	Chemical	MESH:C122128
34587977	1883	1887	INMT	Gene	21743
34587977	1895	1898	PCa	Disease	MESH:D011471
34587977	1981	1985	INMT	Gene	21743
34587977	2003	2008	SMYD3	Gene	69726
34587977	2091	2095	CRPC	Disease	MESH:D064129
34587977	Negative_Correlation	MESH:D004130	21743
34587977	Positive_Correlation	MESH:D064129	21743
34587977	Association	MESH:C122128	21743
34587977	Negative_Correlation	MESH:C008493	MESH:D012643
34587977	Association	MESH:D011471	21743
34587977	Association	MESH:D064129	69726
34587977	Association	21743	69726
34587977	Negative_Correlation	MESH:D004130	MESH:D064129

